ImmunoVaccine (OTCQX:IMMVF; TSX:IMV) reported positive top-line results from its Phase 1 trial evaluating the safety and immunogenicity of DPX-RSV, its DepoVax-based, small B cell epitope peptide vaccine candidate for respiratory syncytial virus (RSV).
The results six months or more after vaccination confirmed interim data on the ability of DepoVax-formulated antigens to generate a relevant, durable immune response.
Specifically, the study demonstrated that the vaccine had a positive safety profile and was well tolerated with no serious adverse events among all study participants. Antigen-specific immune responses were detected at least six months after the last vaccination in 93% (15/16) of patients receiving DPX-RSV, in both low-dose (8/8 participants) and high-dose (7/8 participants) cohorts.
"We are thrilled with these results, as they go beyond our initial expectations,” CEO, Frederic Ors, said in a statement. “We believe that our differentiated approach, along with this topline data, position DPX-RSV to address a significant unmet medical need in the RSV market."
Currently, there is no vaccine available for RSV. ImmunoVaccine has an exclusive worldwide license on applications that target the SH ectodomain antigen in RSV and is in discussions with multiple potential partners to identify the best possible path forward for the further clinical development of DPX-RSV.